Cargando…
Serendipitous synergism – an exceptional response to treatment with pembrolizumab in the course of a natural immunovirotherapy: a case report and review of the literature
Immune checkpoint inhibitors (ICIs) are the current guideline recommended treatment for many malignancies considered to be terminal. Despite considerable advances, their utility remains limited, and the field requires synergistic partners to further improve outcomes. Oncolytic viruses (OV) are emerg...
Autores principales: | Khoury, Lara M., Burcher, Kimberly M., Ng, Ronald T., Song, Alexander H., Chang, Mark J., Gavrila, Elena, Bloomer, Chance H., Robinson, Mac B., Kouri, Brian E., Waltonen, Joshua D., Bunch, Paul M., Lauer, Ulrich M., Porosnicu, Mercedes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597005/ https://www.ncbi.nlm.nih.gov/pubmed/36312814 http://dx.doi.org/10.1177/17588359221122729 |
Ejemplares similares
-
Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature
por: Bloomer, Chance H., et al.
Publicado: (2023) -
A Review of the Role of Oral Microbiome in the Development, Detection, and Management of Head and Neck Squamous Cell Cancers
por: Burcher, Kimberly M., et al.
Publicado: (2022) -
Immunovirotherapy for glioblastoma
por: Ning, Jianfang, et al.
Publicado: (2014) -
In Reply: TP53 Alteration Status and Tumor Mutational Burden Score: Prevalence and Prognosis in Head and Neck Squamous Cell Carcinoma
por: Burcher, Kimberly M, et al.
Publicado: (2022) -
Immunovirotherapy for the treatment of glioblastoma
por: Cheema, Tooba A, et al.
Publicado: (2014)